MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations

MannKind logo with Healthcare background
Image from MarketBeat Media, LLC.

MannKind NASDAQ: MNKD is focusing on the launch of its FUROSCIX ReadyFlow autoinjector, pediatric AFREZZA and the development of inhaled nintedanib, CEO Michael Castagna said at the UBS Biopharma Conference in London.

Castagna said MannKind expects to be profitable next year after a period of investment that reduced profitability. The company is also considering how to use capital from its partnership with United Therapeutics, including to expand existing products, acquire additional assets or pay down debt.

FUROSCIX Conversion Ahead of Expectations

MannKind acquired scPharmaceuticals and its FUROSCIX product as part of an effort to diversify revenue beyond its inhalation technology platform. Castagna said the ReadyFlow format received approval in the third quarter.

In roughly the first six weeks after launch, nearly 75% to 80% of patients converted to ReadyFlow from the on-body infusor, Castagna said. That was a couple of quarters ahead of the company’s expectations. He said the fourth quarter should be the company’s best ever for ReadyFlow and MannKind overall.

Castagna said ReadyFlow could expand FUROSCIX’s opportunity in hospitals. He noted that about 90% of sales of the on-body infusor had been outside the hospital setting. A planned 40-milligram presentation could also broaden the range of prescribers and dosing options, he said.

FDA Meeting Clears Path for U.S. Trial Sites

For MNKD-201, MannKind’s inhaled nintedanib program, Castagna said the Food and Drug Administration indicated the company could proceed with adding U.S. sites to its planned global Phase 2 trial.

MannKind has targeted the first half of 2028 to complete the trial, but Castagna said U.S. sites could help accelerate that timeline. He did not provide updated guidance. The company expects to need about 150 patients across close to 100 sites, with a preliminary allocation of approximately 85 sites outside the U.S. and 15 in the U.S., although that mix remains under evaluation.

Castagna said results from the Phase 1b INFLO-1 study gave MannKind confidence to reduce the burden of repeated lung-function testing in the next trial. He said the company will focus on efficacy in Phase 2 after assessing tolerability and safety in earlier studies.

The CEO said MannKind is seeking to develop an inhaled treatment with efficacy comparable to or better than oral nintedanib and improved tolerability. He said no diarrhea had been reported in the company’s trials, which had included more than 40 patients and 700 doses. Those comments describe the company’s development objective and early experience, not a demonstration of Phase 2 efficacy.

United Therapeutics Partnership and AFREZZA

MannKind’s partnership with United Therapeutics provides royalties and manufacturing revenue tied to TYVASO DPI. Castagna said MannKind has previously projected more than $1 billion in combined royalties, milestones and manufacturing revenue from the partnership between now and 2030.

United Therapeutics is pursuing additional fibrotic lung disease opportunities, initially using a nebulized product for idiopathic pulmonary fibrosis, Castagna said. He added that MannKind recently released data from a study in those patients showing that the inhaled powders were tolerable and that no participants discontinued because of cough.

For AFREZZA, Castagna said pediatric patient starts had recently reached records and refills were beginning to build. He said one in three pediatric endocrinologists had written an initial prescription, and the top 60 centers had done so.

MannKind pulled back its focus on adults this year, and that segment shrank, Castagna said. The company plans to refocus on adult growth next year while continuing to expand the pediatric launch. He said total and new prescription figures remain directionally useful indicators for investors, though they do not capture every channel.

Capital Allocation and Future Deals

Castagna said MannKind is not in a rush to make another acquisition and has enough to execute over the next 12 to 18 months. Potential additions could complement its existing businesses in areas such as cardiology, nephrology, endocrinology and pulmonary diseases, he said.

The CEO added that MannKind’s acquisition of scPharmaceuticals was intended to broaden the company beyond inhalation. Its focus on drug-device combinations could extend to injections and other delivery methods, he said.

About MannKind (NASDAQ:MNKD)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MannKind Right Now?

Before you consider MannKind, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.

While MannKind currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines